User profiles for H. L. McLeod
 | Howard McLeodUtah Tech University Verified email at utahtech.edu Cited by 55214 |
Pharmacogenomics—drug disposition, drug targets, and side effects
It is well recognized that different patients respond in different ways to the same medication.
These differences are often greater among members of a population than they are within the …
These differences are often greater among members of a population than they are within the …
[HTML][HTML] Genomics and drug response
L Wang, HL McLeod… - New England Journal of …, 2011 - Mass Medical Soc
Genomics and Drug Response | NEJM Skip to main content NEJM Group Follow Us Facebook
Twitter Instagram YouTube LinkedIn Prepare to become a physician, build your knowledge …
Twitter Instagram YouTube LinkedIn Prepare to become a physician, build your knowledge …
Platinum neurotoxicity pharmacogenetics
SR McWhinney, RM Goldberg, HL McLeod - Molecular cancer therapeutics, 2009 - AACR
Cisplatin, carboplatin, and oxaliplatin anticancer drugs are commonly used to treat lung,
colorectal, ovarian, breast, head and neck, and genitourinary cancers. However, the efficacy of …
colorectal, ovarian, breast, head and neck, and genitourinary cancers. However, the efficacy of …
[HTML][HTML] Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
…, DA Nickerson, CS Eby, HL McLeod… - … England Journal of …, 2005 - Mass Medical Soc
Background The management of warfarin therapy is complicated by a wide variation among
patients in drug response. Variants in the gene encoding vitamin K epoxide reductase …
patients in drug response. Variants in the gene encoding vitamin K epoxide reductase …
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
Initiation of warfarin therapy using trial‐and‐error dosing is problematic. Our goal was to
develop and validate a pharmacogenetic algorithm. In the derivation cohort of 1,015 participants…
develop and validate a pharmacogenetic algorithm. In the derivation cohort of 1,015 participants…
MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity
…, DA Price-Evans, HL McLeod - Pharmacogenetics …, 2001 - journals.lww.com
P-glycoprotein (PGP), the product of the multidrug resistance gene (MDR1), acts as an
energy-dependent efflux pump that exports its substrates out of the cell. PGP expression is an …
energy-dependent efflux pump that exports its substrates out of the cell. PGP expression is an …
Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia
Thiopurine methyltransferase (TPMT) catalyses the S-methylation of thiopurines, including 6-mercaptopurine
and 6-thioguanine. TPMT activity exhibits genetic polymorphism, with …
and 6-thioguanine. TPMT activity exhibits genetic polymorphism, with …
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs
Consistent with its highest abundance in humans, cytochrome P450 (CYP) 3A is responsible
for the metabolism of about 60% of currently known drugs. However, this unusual low …
for the metabolism of about 60% of currently known drugs. However, this unusual low …
UGT1A1* 28 genotype and irinotecan-induced neutropenia: dose matters
…, P Qu, JG Ibrahim, HL McLeod - Journal of the …, 2007 - academic.oup.com
The Food and Drug Administration and Pfizer changed the package insert for irinotecan to
include a patient's UGT1A1*28 genotype as a risk factor for severe neutropenia on the basis …
include a patient's UGT1A1*28 genotype as a risk factor for severe neutropenia on the basis …
PI3K/Akt/mTOR pathway as a target for cancer therapy
D Morgensztern, HL McLeod - Anti-cancer drugs, 2005 - journals.lww.com
The PI3K/Akt/mTOR pathway regulates several normal cellular functions that are also
critical for tumorigenesis, including cellular proliferation, growth, survival and mobility. …
critical for tumorigenesis, including cellular proliferation, growth, survival and mobility. …